Disruption of cotranscriptional splicing suggests RBM39 is a therapeutic target in acute lymphoblastic leukemia

• Published in: Blood 2024-12, Vol.144 (23), p.2417-2431
• Main Authors: Jin, Qi, Harris, Ethan, Myers, Jacquelyn A., Mehmood, Rashid, Cotton, Anitria, Shirnekhi, Hazheen K., Baggett, David W., Wen, Jeremy Qiang, Schild, Andrew B., Bhansali, Rahul S., Klein, Jonathon, Narina, Shilpa, Pieters, Tim, Yoshimi, Akihide, Pruett-Miller, Shondra M., Kriwacki, Richard, Abdel-Wahab, Omar, Malinge, Sebastien, Ntziachristos, Panagiotis, Obeng, Esther A., Crispino, John D.
• Format: Article
• Language: English
• Subjects: Animals; Cell Line, Tumor; Cyclin-Dependent Kinase 9 - antagonists & inhibitors; Cyclin-Dependent Kinase 9 - genetics; Cyclin-Dependent Kinase 9 - metabolism; Exons; Humans; Lymphoid Neoplasia; Mice; Nonsense Mediated mRNA Decay; Precursor Cell Lymphoblastic Leukemia-Lymphoma - drug therapy; Precursor Cell Lymphoblastic Leukemia-Lymphoma - genetics; Precursor Cell Lymphoblastic Leukemia-Lymphoma - metabolism; Precursor Cell Lymphoblastic Leukemia-Lymphoma - pathology; RNA Polymerase II - genetics; RNA Polymerase II - metabolism; RNA Splicing; RNA-Binding Proteins - genetics; RNA-Binding Proteins - metabolism; Xenograft Model Antitumor Assays
• ISSN: 0006-4971; 1528-0020; 1528-0020
• DOI: 10.1182/blood.2024024281

•Alternative splicing that is controlled by the cotranscriptional splicing complex may be therapeutically tractable in high-risk B-ALL.•Models of high-risk B-ALL are susceptible to pharmacologic and genetic inhibition of RBM39. [Display omitted] There are only a few options for patients with relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL), thus, this is a major area of unmet medical need. In this study, we reveal that the inclusion of a poison exon in RBM39, which could be induced by both CDK9 or CDK9 independent cyclin-dependent kinases, mitogen-activated protein kinases, glycogen synthase kinases, CDC-like kinases (CMGC) kinase inhibition, is recognized by the nonsense-mediated messenger RNA decay pathway for degradation. Targeting this poison exon in RBM39 with CMGC inhibitors led to protein downregulation and the inhibition of ALL growth, particularly in relapsed/refractory B-ALL. Mechanistically, disruption of cotranscriptional splicing by the inhibition of CMGC kinases, including DYRK1A, or inhibition of CDK9, which phosphorylate the C-terminal domain of RNA polymerase II (Pol II), led to alteration in the SF3B1 and Pol II association. Disruption of SF3B1 and the transcriptional elongation complex altered Pol II pausing, which promoted the inclusion of a poison exon in RBM39. Moreover, RBM39 ablation suppressed the growth of human B-ALL, and targeting RBM39 with sulfonamides, which degrade RBM39 protein, showed strong antitumor activity in preclinical models. Our data reveal that relapsed/refractory B-ALL is susceptible to pharmacologic and genetic inhibition of RBM39 and provide 2 potential strategies to target this axis. While splicing factor mutations are frequent findings in myeloid malignancy, they are not seen in acute lymphoblastic leukemia (ALL); however, there is evidence that dysregulation of splicing is common in ALL cells. Jin and colleagues investigated splicing in ALL and report that downregulation of RBM39, a component of the splicing machinery, suppresses human B-cell ALL growth in vitro and in vivo. RBM39 may be a novel therapeutic target in relapsed/refractory ALL.